A phase II study of Erlotinib for elderly patients previously treated non-small cell lung cancer without epidermal growth factor receptor mutatio
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000004561
- Lead Sponsor
- Fukushima Medical University, cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 44
Not provided
1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis 2)Patients with massive pleural or pericardial effusion,or ascites 3)Patients with active severe infections 4)Cases with past history of administration of HER related agents 5) Impossible cases with oral administration 6)Patients with active opthalmological disease 7)Patients with current or previous (within one year) history of gastrointestinal perforation 8)Patients with uncontrollable gastrointestinal ulceration 9)Pregnancy or lactation 10)Patients with symptomatic brain metastasis 11)Patients with active concomitant malignancy 12)Patients with uncontrollable diabetes mellitus 13)Patients with uncontrollable complications 14)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method desease control rate, progression-free survival, overall survival, safety